1-[1-(Trifluoromethyl)cyclopropyl]ethan-1-ol | 2229383-28-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代醇
• 英文名称: 1-[1-(Trifluoromethyl)cyclopropyl]ethan-1-ol
• 英文别名: 1-[1-(trifluoromethyl)cyclopropyl]ethanol
• CAS: 2229383-28-0
• 化学式: C₆H₉F₃O
• 分子量: 154.13
• InChiKey: YDGHMPLDQCHQAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20160122335A1

  公开（公告）日：2016-05-05

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 5 , A 1 , A 2 , and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及公式I的化合物，其中：R1、R2、R3、R5、A1、A2和在规范中定义。该发明还涉及一种治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病为类风湿性关节炎或银屑病。该发明还涉及通过给予至少一种权利要求1的化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。
• AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORGAMMAT
  申请人：Janssen Pharmaceutica NV

  公开号：EP3212642B1

  公开（公告）日：2019-10-30
• US9845319B2
  申请人：——

  公开号：US9845319B2

  公开（公告）日：2017-12-19
• [EN] PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT<br/>[FR] PYRAZOLES SUBSTITUÉS PAR PHÉNYLE UTILISÉS EN TANT QUE MODULATEURS DE RORYT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243999A1

  公开（公告）日：2019-12-26

  The present invention comprises compounds of Formula (I). wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-y-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORĻγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).